Global investor rights law firm Rosen Law Firm announced on April 12, 2026, that it is investigating potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE American: KAPA). The investigation centers on allegations that Kairos Pharma may have issued materially misleading business information to the public.
"If you purchased Kairos Pharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement," the law firm stated, indicating that they are preparing a class action to seek recovery of investor losses. The firm encourages investors to select qualified counsel with a proven track record in securities class actions.
The probe by Rosen Law Firm could lead to a significant class-action lawsuit, which would pose notable financial and reputational risks for Kairos Pharma. Such legal action often leads to a decline in stock price as investors react to the uncertainty surrounding the company's financial disclosures and legal standing.
Rosen Law Firm has a history of securing large settlements for investors, including the largest ever securities class action settlement against a Chinese company. The firm has been consistently ranked in the top four for securities class action settlements each year since 2013 and secured over $438 million for investors in 2019 alone.
This article is for informational purposes only and does not constitute investment advice.
